文献速递肾小球疾病

乙型肝炎病毒感染状态与IgA肾病临床结局

Hepatitis B Virus Status and Clinical Outcomes in IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2024-01-10

本研究在1961例IgA肾病患者的随访数据库中,分析了慢性HBV感染、已缓解HBV感染及肾组织HBV抗原沉积三种状态与IgA肾病进展(eGFR下降>40%)的关系。多因素病因特异性风险模型显示,慢性HBV感染是IgA肾病进展的独立危险因素,而已缓解HBV感染、肾组织HBV沉积及抗HBV治疗均与肾脏结局无显著关联。

要点

  • 慢性HBV感染是IgA肾病进展的独立危险因素。
  • 已缓解HBV感染与IgA肾病进展无显著关联。
  • 肾组织HBV沉积及抗HBV治疗未显著影响肾脏结局。

核心结论

  • 慢性HBV感染是IgA肾病进展的独立危险因素,已缓解HBV感染则不是。
  • 肾组织HBV沉积及抗HBV药物使用不影响合并HBV感染的IgA肾病患者肾脏病进展。

研究设计与样本

  • 基于1961例IgA肾病患者随访数据库的队列研究,分析慢性HBV感染、已缓解HBV感染及肾组织HBV抗原沉积三种状态。
  • 采用多因素病因特异性风险模型分析HBV状态与IgA肾病进展的关系,并进行倾向性评分匹配分析。

主要发现

  • 慢性HBV感染与IgA肾病进展独立相关:匹配前HR 1.61(95%CI 1.06-2.44,P=0.024),倾向性评分匹配后HR 1.74(95%CI 1.28-2.37,P<0.001)。
  • 已缓解HBV感染与IgA肾病进展无显著关联(HR 1.01,95%CI 0.67-1.52,P=0.969)。
  • 肾组织HBV沉积及抗HBV治疗与肾脏结局无显著关联(P>0.05)。

关键数值与推荐

  • IgA肾病进展定义为估算肾小球滤过率(eGFR)下降>40%。
  • 慢性HBV感染为独立危险因素:匹配前HR 1.61(95%CI 1.06-2.44,P=0.024);匹配后HR 1.74(95%CI 1.28-2.37,P<0.001)。
  • 已缓解HBV感染HR 1.01(95%CI 0.67-1.52,P=0.969)。
  • 肾组织HBV沉积及抗HBV治疗P>0.05。

临床怎么用

  • 对合并慢性HBV感染的IgA肾病患者,应加强HBV感染的管理。
  • 已缓解HBV感染、肾组织HBV沉积及抗HBV治疗状态不改变IgA肾病进展风险管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immunoglobulin A nephropathy (IgAN) has been reported to coexist with hepatitis B virus (HBV) infection. Despite the clinical significance of this association, there is a lack of comprehensive research investigating the impact of various common conditions following HBV infection and the potential influence of anti-HBV therapy on the progression of IgAN. METHODS: We investigated 3 distinct states of HBV infection, including chronic HBV infection, resolved HBV infection, and the deposition of hepatitis B antigens in renal tissue, in a follow-up database of 1961 patients with IgAN. IgAN progression was defined as a loss of estimated glomerular filtration rate (eGFR) >40%. Multivariable cause-specific hazards models to analyze the relationship between HBV states and IgAN progression. RESULTS: Chronic HBV infection was identified as an independent risk factor for IgAN progression, supported by both prematching analysis (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.06-2.44; P = 0.024) and propensity-score matching analysis (HR, 1.74; 95% CI 1.28-2.37; P < 0.001). Conversely, resolved HBV infection showed no significant association with IgAN progression (HR, 1.01; 95% CI 0.67-1.52; P = 0.969). Moreover, the presence of HBV deposition in the kidneys and the utilization of anti-HBV therapy did not appear to be significant risk factors for renal outcomes (P > 0.05). CONCLUSION: Chronic HBV infection is an independent risk factor for IgAN progression, whereas resolved HBV infection is not. In patients with IgAN, management of concurrent chronic HBV infection should be enhanced. The presence of HBV deposition in the kidneys and the use of anti-HBV medications do not impact the kidney disease progression in patients with IgAN with concurrent HBV infection.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gao MZ, Xu LL, Li Y, et al. Hepatitis B Virus Status and Clinical Outcomes in IgA Nephropathy. Kidney Int Rep. 2024. PMID: 38765575. doi:10.1016/j.ekir.2024.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。